Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00228-015-1956-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies.
Lancet Child Adolesc Health
January 2019
Division of Epidemiology, Food and Drug Administration, Silver Spring, MD, USA.
Background: Serious and fatal deferasirox-induced kidney injury has been reported in paediatric patients. This study aimed to investigate the effects of deferasirox dose and serum ferritin concentrations on kidney function and the effect of impaired kidney function on dose-normalised deferasirox minimum plasma concentration (C).
Methods: We did a case-control analysis using pooled data from ten clinical studies.
Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells.
Sci Rep
January 2017
Research Institute-Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain.
Iron deficiency has been associated with kidney injury. Deferasirox is an oral iron chelator used to treat blood transfusion-related iron overload. Nephrotoxicity is the most serious and common adverse effect of deferasirox and may present as an acute or chronic kidney disease.
View Article and Find Full Text PDFDeferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.
Eur J Clin Pharmacol
February 2016
Department of Biomedical and Clinical Sciences, Unit of Clinical Pharmacology, "Luigi Sacco" University Hospital, University of Milano, Milan, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!